JP2000511407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000511407A5 JP2000511407A5 JP1997538216A JP53821697A JP2000511407A5 JP 2000511407 A5 JP2000511407 A5 JP 2000511407A5 JP 1997538216 A JP1997538216 A JP 1997538216A JP 53821697 A JP53821697 A JP 53821697A JP 2000511407 A5 JP2000511407 A5 JP 2000511407A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1611796P | 1996-04-24 | 1996-04-24 | |
| US1778596P | 1996-05-15 | 1996-05-15 | |
| US60/016,117 | 1996-05-15 | ||
| US60/017,785 | 1996-05-15 | ||
| PCT/US1997/006563 WO1997040145A1 (en) | 1996-04-24 | 1997-04-24 | Inactivation resistant factor viii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007101700A Division JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000511407A JP2000511407A (ja) | 2000-09-05 |
| JP2000511407A5 true JP2000511407A5 (enExample) | 2004-12-02 |
| JP3987114B2 JP3987114B2 (ja) | 2007-10-03 |
Family
ID=26688196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53821697A Expired - Fee Related JP3987114B2 (ja) | 1996-04-24 | 1997-04-24 | 不活性化耐性第▲８▼因子 |
| JP2007101700A Expired - Fee Related JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007101700A Expired - Fee Related JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6838437B2 (enExample) |
| EP (3) | EP1754718B1 (enExample) |
| JP (2) | JP3987114B2 (enExample) |
| AT (2) | ATE319817T1 (enExample) |
| AU (1) | AU3202797A (enExample) |
| CA (1) | CA2252896C (enExample) |
| DE (2) | DE69740154D1 (enExample) |
| DK (1) | DK1754718T3 (enExample) |
| PT (1) | PT1754718E (enExample) |
| WO (1) | WO1997040145A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713303B2 (en) * | 1995-06-12 | 1999-11-25 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation |
| US20040092442A1 (en) * | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| ATE319817T1 (de) | 1996-04-24 | 2006-03-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
| US8183344B2 (en) | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
| WO1999041385A1 (en) * | 1998-02-13 | 1999-08-19 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
| JP2005518181A (ja) * | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物 |
| WO2003100053A1 (en) * | 2002-05-22 | 2003-12-04 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia a |
| US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| WO2006067230A1 (en) * | 2004-12-23 | 2006-06-29 | Novo Nordisk Health Care Ag | Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest |
| AU2006233638A1 (en) * | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation Factor VIII with enhanced stability and its derivates |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2008005847A2 (en) * | 2006-06-30 | 2008-01-10 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| US20090203077A1 (en) * | 2006-06-30 | 2009-08-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| MX351220B (es) * | 2010-11-05 | 2017-10-05 | Baxalta GmbH | Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada. |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| CN103917554B (zh) | 2011-10-18 | 2017-03-08 | 杰特有限公司 | 用于改善重构后纯化的因子viii的稳定性的方法 |
| US9511123B2 (en) | 2011-10-18 | 2016-12-06 | Csl Behring Gmbh | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII |
| EP2768522B1 (en) | 2011-10-18 | 2016-07-27 | CSL Behring GmbH | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
| DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
| US20150337028A1 (en) * | 2012-09-12 | 2015-11-26 | Centre For Bioseparation Technology-Vit | Double Mutant Coagulation Factor VIII and Methods Thereof |
| MX2015006738A (es) | 2012-11-29 | 2015-08-05 | Bayer Healthcare Llc | Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos. |
| RU2015125349A (ru) * | 2012-11-29 | 2017-01-10 | Байер Хелскеа Ллк | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) |
| US9914764B2 (en) | 2013-03-15 | 2018-03-13 | Bayer Healthcare, Llc | Variant factor VIII polypeptides and methods of their production and use |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| WO2015132724A1 (en) | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
| ES2844232T3 (es) | 2014-07-02 | 2021-07-21 | CSL Behring Lengnau AG | Factor de Von Willebrand modificado |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| CA2978134A1 (en) * | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Compounds for improving the half-life of von willebrand factor |
| SG10201910900WA (en) | 2015-05-22 | 2020-01-30 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| MX2017014503A (es) | 2015-05-22 | 2018-08-01 | CSL Behring Lengnau AG | Polipeptidos de factor de von willebrand truncado para tratar hemofilia. |
| WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
| JP6851381B6 (ja) | 2016-01-07 | 2021-04-21 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 変異切断型フォンウィルブランド因子 |
| KR20190073576A (ko) | 2016-11-11 | 2019-06-26 | 체에스엘 베링 렝나우 아게 | 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 |
| SG10201912360SA (en) | 2016-11-11 | 2020-02-27 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| CN120865384A (zh) * | 2018-10-23 | 2025-10-31 | 费城儿童医院 | 用于调节因子viii功能的组合物和方法 |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| CN114828870A (zh) * | 2019-12-06 | 2022-07-29 | 费城儿童医院 | 用于调节因子viii功能的组合物和方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214033A (en) * | 1983-03-31 | 1993-05-25 | Scripps Clinic & Research Foundation | Factor VIII coagulant polypeptides |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5045455A (en) * | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
| SE8501050D0 (sv) | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| CA1341174C (en) | 1985-04-12 | 2001-01-30 | John J. Toole Jr. | Procoagulant proteins derived from factor viii: c |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| DE3785102T2 (de) | 1986-01-03 | 1993-07-22 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ-proteinen. |
| AT388079B (de) | 1986-04-18 | 1989-04-25 | Helmut Ing Koenig | Backofen |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| FI922204A0 (fi) | 1989-11-17 | 1992-05-14 | Novo Nordisk As | Proteinkomplex med faktor viii:c- aktivitet och framstaellning av desamma. |
| US5661008A (en) * | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5563045A (en) * | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| WO1997003194A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Lysine 1689 factor viii:c polypeptide analogs |
| WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| ATE319817T1 (de) * | 1996-04-24 | 2006-03-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
-
1997
- 1997-04-24 AT AT97927596T patent/ATE319817T1/de not_active IP Right Cessation
- 1997-04-24 JP JP53821697A patent/JP3987114B2/ja not_active Expired - Fee Related
- 1997-04-24 WO PCT/US1997/006563 patent/WO1997040145A1/en not_active Ceased
- 1997-04-24 DE DE69740154T patent/DE69740154D1/de not_active Expired - Lifetime
- 1997-04-24 EP EP06004484A patent/EP1754718B1/en not_active Expired - Lifetime
- 1997-04-24 PT PT06004484T patent/PT1754718E/pt unknown
- 1997-04-24 AT AT06004484T patent/ATE502958T1/de active
- 1997-04-24 DK DK06004484.9T patent/DK1754718T3/da active
- 1997-04-24 DE DE69735421T patent/DE69735421T2/de not_active Expired - Lifetime
- 1997-04-24 CA CA002252896A patent/CA2252896C/en not_active Expired - Fee Related
- 1997-04-24 EP EP97927596A patent/EP0910628B1/en not_active Expired - Lifetime
- 1997-04-24 AU AU32027/97A patent/AU3202797A/en not_active Abandoned
- 1997-04-24 EP EP10157809A patent/EP2202242A1/en not_active Withdrawn
-
2001
- 2001-04-11 US US09/819,098 patent/US6838437B2/en not_active Expired - Fee Related
-
2004
- 2004-10-26 US US10/974,534 patent/US7459534B2/en not_active Expired - Fee Related
-
2007
- 2007-04-09 JP JP2007101700A patent/JP4250661B2/ja not_active Expired - Fee Related